WAMPOCAP Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Wampocap, and when can generic versions of Wampocap launch?
Wampocap is a drug marketed by Medpointe Pharm Hlc and is included in one NDA.
The generic ingredient in WAMPOCAP is niacin. There are fourteen drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the niacin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Wampocap
A generic version of WAMPOCAP was approved as niacin by BARR on April 14th, 2005.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for WAMPOCAP?
- What are the global sales for WAMPOCAP?
- What is Average Wholesale Price for WAMPOCAP?
Summary for WAMPOCAP
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 212 |
| Patent Applications: | 4,087 |
| DailyMed Link: | WAMPOCAP at DailyMed |
US Patents and Regulatory Information for WAMPOCAP
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medpointe Pharm Hlc | WAMPOCAP | niacin | CAPSULE;ORAL | 011073-003 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
